Erratum to: Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial

Masson, Serge; Caironi, Pietro; Fanizza, Caterina; Thomae, R; Bernasconi, Roberto; Noto, Andrea; Oggioni, R; Pasetti, G; Romero, Marilena; Tognoni, Gianni; Latini, Roberto; Gattinoni, Luciano

doi:10.1007/s00134-015-3982-z

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 Presepsin is a rapidly responding biomarker for bacterial and fungal infections. Baseline presepsin levels have been shown to predict mortality 33,34 and correlate with sepsis disease severity. 33 Furthermore, the dynamic time course of presepsin also predicts survival.…”

Section: Presepsinmentioning

confidence: 99%

See 1 more Smart Citation

Biomarker‐Guided Individualization of Antibiotic Therapy

Aulin

Lange

Saleh

et al. 2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Treatment failure of antibiotic therapy due to insufficient efficacy or occurrence of toxicity is a major clinical challenge, and is expected to become even more urgent with the global rise of antibiotic resistance. Strategies to optimize treatment in individual patients are therefore of crucial importance. Currently, therapeutic drug monitoring plays an important role in optimizing antibiotic exposure to reduce treatment failure and toxicity. Biomarker-based strategies may be a powerful tool to further quantify and monitor antibiotic treatment response, and reduce variation in treatment response between patients. Host response biomarkers, such as CRP, procalcitonin, IL-6, and presepsin, could potentially carry significant information to be utilized for treatment individualization. To achieve this, the complex interactions among immune system, pathogen, drug, and biomarker need to be better understood and characterized. The purpose of this tutorial is to discuss the use and evidence of currently available biomarker-based approaches to inform antibiotic treatment. To this end, we also included a discussion on how treatment response biomarker data from preclinical, healthy volunteer, and patient-based studies can be further characterized using pharmacometric and system pharmacology based modeling approaches. As an illustrative example of how such modeling strategies can be used, we describe a case study in which we quantitatively characterize procalcitonin dynamics in relation to antibiotic treatments in patients with sepsis.

show abstract

Section: Presepsinmentioning

confidence: 99%

“…Baseline presepsin levels have been shown to predict mortality 33,34 and correlate with sepsis disease severity. 33 Furthermore, the dynamic time course of presepsin also predicts survival. 34 Biomarker dynamics.…”

Section: Presepsinmentioning

confidence: 99%

Biomarker‐Guided Individualization of Antibiotic Therapy

Aulin

Lange

Saleh

et al. 2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…• soluble CD14 blood concentrations correlate with sepsis severity and predicted 30-day and 6-month mortality [149] • soluble CD14 plasma concentrations positively correlate with ICU treatment and 90-day mortality of sepsis patients (n = 997) [150,151] CD16 [72,73,152] (ADAM17)…”

Section: Substrate (Protease)mentioning

confidence: 99%

Meprin and ADAM proteases as triggers of systemic inflammation in sepsis

Rahn

Becker‐Pauly

2021

FEBS Letters

View full text Add to dashboard Cite

Systemic inflammatory disorders (SIDs) comprise a broad range of diseases characterized by dysregulated excessive innate immune responses. Severe forms of SIDs can lead to organ failure and death, and their increasing incidence represents a major issue for the healthcare system. Protease‐mediated ectodomain shedding of cytokines and their receptors represents a central mechanism in the regulation of inflammatory responses. The metalloprotease A disintegrin and metalloproteinase (ADAM) 17 is the best‐characterized ectodomain sheddase capable of releasing TNF‐α and soluble IL‐6 receptor, which are decisive factors of systemic inflammation. Recently, meprin metalloproteases were also identified as IL‐6 receptor sheddases and activators of the pro‐inflammatory cytokines IL‐1β and IL‐18. In different mouse models of SID, particularly those mimicking a sepsis‐like phenotype, ADAM17 and meprins have been found to promote disease progression. In this review, we summarize the role of ADAM10, ADAM17, and meprins in the onset and progression of sepsis and discuss their potential as therapeutic targets.

show abstract